Biotech Values

[jq1234]

FDA Advisory Panel on Xarelto for the prevention of
stroke and systemic embolism

On September 8, 2011, the committee will discuss new drug application (NDA)
202439, rivaroxaban tablets, submitted by Johnson & Johnson Pharmaceutical Research and
Development, L.L.C., on behalf of Ortho-McNeil-Janssen-Pharmaceuticals, for the prevention of
stroke and systemic embolism (blood clots other than in the head) in patients with nonvalvular
atrial fibrillation (abnormally rapid contractions of the atria, the upper chambers of the heart).

http://www.ofr.gov/OFRUpload/OFRData/2011-16862_PI.pdf